Alkermes has launched the Brilliance Studies, a Phase 3 clinical trial program that will evaluate the safety and effectiveness of alixorexton, its once-daily oral therapy candidate for people with narcolepsy types 1 and 2. The new program builds on findings of Phase 2 trials showing that alixorexton…
News
Modafinil, sold under the brand name Provigil among others, significantly eases excessive daytime sleepiness in people with narcolepsy, according to a new systematic review and meta-analysis. Across more than a half dozen studies involving nearly 1,000 patients, modafinil was found to increase wakefulness and reduce subjective sleepiness…
A new data-driven model has identified narcolepsy — a condition characterized by the brain’s inability to regulate sleep-wake cycles — as a key driver of excessive daytime sleepiness (EDS), which is marked by chronic, intense drowsiness that can occur throughout the day, a U.S. study found. The model, generated…